Todd C. Brady is listed as a director on 10 SEC Form D filings by 3 issuers between Feb 2010 and Sep 2017: Outlook Therapeutics, Inc. (Iselin, NJ — biotechnology — 2015–2017; $60M reported sold to 21 investors), CANTEX PHARMACEUTICALS, INC. (Weston, FL — pharmaceuticals — 2010–2014; $4.39M reported sold to 7 investors) and Asmacure, Inc. (Quebec, Quebec, Canada (as filed: A8) — other health care — 2010–2011; $4M reported sold to 4 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as director, over about 7 years. Across those companies the filings report $68.4M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 5 bankruptcy cases matching the name listed in Key records below.
What this means 5 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 10 public filings for Todd C. Brady and found 12 differences, 1 worth asking the sponsor about: Form D filed 66 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.